Production of biologically active complement factor H in therapeutically useful quantities
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Human complement factor H (FH), an abundant 155-kDa plasma glycoprotein with 40 disulphide bonds, regulates the alternative-pathway complement cascade. Mutations and single nucleotide polymorphisms in the FH gene predispose to development of age-related macular degeneration, atypical haemolytic uraemic syndrome and dense deposit disease. Supplementation with FH variants protective against disease is an enticing therapeutic prospect. Current sources of therapeutic FH are restricted to human blood plasma highlighting a need for recombinant material. Previously FH expression in cultured plant, mammalian or insect cells yielded protein amounts inadequate for full characterisation, and orders of magnitude below therapeutic usefulness. Here, the V62,Y402 variant of FH has been produced recombinantly (rFH) in Pichia pastoris cells. Codon-optimisation proved essential whilst exploitation of the yeast mating α-factor peptide ensured secretion. We thereby produced multiple 10s-of-milligram of rFH. Following endoglycosidase H digestion of N-linked glycans, rFH (with eight residual N-acetylglucosamine moieties) was purified on heparin-affinity resin and anion-exchange chromatography. Full-length rFH was verified by mass spectrometry and Western blot using monoclonal antibodies to the C-terminus. Recombinant FH is a single non-aggregated species (by dynamic light scattering) and fully functional in biochemical and biological assays. An additional version of rFH was produced in which eight N-glycosylation sequons were ablated by Asn–Gln substitutions resulting in a glycan-devoid product. Successful production of rFH in this potentially very highly expressing system makes production of therapeutically useful quantities economically viable. Furthermore, ease of genetic manipulation in P. pastoris would allow production of engineered FH versions with enhanced pharmacokinetic and pharmacodynamic properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Complement factor H polymorphism and age-related macular degeneration
Edwards, A. O., Ritter, R., Abel, K. J., Manning, A., Panhuysen, C., & Farrer, L. A. (2005) · Science · doi:10.1126/science.1110189 · Cited by 2,449
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501536102 · Cited by 1,961 · cited 1×
“This could be especially useful in therapeutic applications since protective haplotypes of FH, in diseases such as AMD, aHUS and DDD, have been identified that would be good candidates for use in therapies based on supplementation of FH in patients who carry at-risk alleles [33,68,69].”
Structural basis for complement factor H linked age-related macular degeneration
Prosser, B. E., Johnson, S., Roversi, P., Herbert, A. P., Blaum, B. S., Tyrrell, J., Jowitt, T. A., Clark, S. J., Tarelli, E., Uhrín, D., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20071069 · Cited by 184 · cited 1×
“Protein production based on expression in engineered Escherichia coli, and refolding of insoluble material, has been used for manufacture of several FH fragments [45,46] but not for production of fulllength FH.”
MethodSelf-citationApplications of yeast in biotechnology: protein production and genetic analysis
Cereghino, G. P. L., & Cregg, J. M. (1999) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(99)00004-x · Cited by 176 · cited 1×
“pastoris grows on simple and inexpensive media, and allows genetic manipulation with relative ease [50].”
BackgroundMontes, T., Goicoechea de Jorge, E., Ramos, R., Gomà, M., Pujol, O., Sánchez-Corral, P., & Rodríguez de Córdoba, S. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.01.027 · Cited by 47
Cited by
Atypical hemolytic uremic syndrome
Loirat, C., & Frémeaux-Bacchi, V. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-60 · Cited by 669
Clark, S. J., Schmidt, C. Q., White, A. M., Hakobyan, S., Morgan, B. P., & Bishop, P. N. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401613 · Cited by 122
Self-citationPaun (2018) · doi:10.1016/j.ophtha.2017.12.023 · Cited by 70
Self versus nonself discrimination by the soluble complement regulators factor H and FHL-1
Dopler, A., Guntau, L., Harder, M. J., Palmer, A., Höchsmann, B., Schrezenmeier, H., Simmet, T., Huber-Lang, M., & Schmidt, C. Q. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1801545 · Cited by 35
“This assay was conducted as previously described (28, 30, 34).”
MethodSelf-citation
Metadata
- Authors
- Schmidt, C. Q., Slingsby, F. C., Richards, A., & Barlow, P. N.
- Venue
- Protein Expression and Purification
- Publisher
- Elsevier BV
- Published
- 2011-04
- Volume
- 76
- Issue
- 2
- Pages
- 254-263
- ISSN
- 1046-5928 (ISSN-L)
- OpenAlex
- W2106080176
- Cited by
- 81
- References
- 7
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Production of biologically active complement factor H in therapeutically useful quantities. https://app.cochat.ai/papers/10.1016/j.pep.2010.12.002
- The paper
- Schmidt, C. Q., Slingsby, F. C., Richards, A., & Barlow, P. N. (2011). Production of biologically active complement factor H in therapeutically useful quantities. Protein Expression and Purification. https://doi.org/10.1016/j.pep.2010.12.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.